Gilead Snags Top Call From Goldman Sachs (GILD)
Gilead Sciences Inc. (NASDAQ: GILD) is trading higher this Monday on a top research upgrade. The biotech was raised to the Conviction Buy List by Goldman Sachs. Its new price target is $46.00 per share. Shares are indicated up 1.6%…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Gilead Sciences Inc. (NASDAQ: GILD) is trading higher this Monday on a top research upgrade. The biotech was raised to the Conviction Buy List by Goldman Sachs. Its new price target is $46.00 per share. Shares are indicated up 1.6% at $39.90 and the 52-week range is $34.45 to $43.49.
Contact [email protected] for any questions or corrections.
Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.
